Every Form 4 that Q32 Bio Inc. (QTTB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow QTTB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QTTB filings page.
Q32 Bio Inc. CEO and director Jodie Pope Morrison reported an automatic sale of 3,221 shares on October 6, 2026, to cover tax withholding obligations tied to vesting of performance-based restricted stock units; the sale was not at her discretion. The reported weighted-average price was $8.3198 per share, with transactions ranging from $8.08 to $8.32. Her direct holdings after the sale were 340,038 shares. No Rule 10b5-1 plan is reported.
Q32 Bio Inc. (QTTB) Chief Scientific Officer Shelia M. Violette sold 917 shares of common stock on October 6, 2026, at a weighted average price of $8.3197 per share. The shares were required to be sold to cover tax withholding obligations tied to vesting performance-based restricted stock units; the sales were automatic and not at her discretion. Her direct holdings after the sale were 126,854 shares. Violette Holdings LLC held 36,277 shares; Violette is its manager and disclaims beneficial ownership except to the extent of her pecuniary interest, if any.
Q32 Bio Inc.'s CFO and President, Lee Kalowski, sold 1,301 common shares on October 6, 2026, at a weighted average price of $8.3198 per share. The shares were sold in multiple transactions priced from $8.08 to $8.32 to cover tax withholding obligations tied to vesting performance-based restricted stock units; the sales were automatic and not at his discretion. He directly held 137,170 shares after the sale. No Rule 10b5-1 plan is reported.
Q32 Bio Inc. director Arthur Tzianabos reported a corrected grant of 10,826 stock options to acquire Common Stock, awarded on June 12, 2026 at an exercise price of $12.64 per share and expiring on June 11, 2036. The options vest and become exercisable in full on the earlier of June 12, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. This amendment updates a Form 4 filed on June 16, 2026 solely to correct the number of options awarded.
Q32 Bio Inc. director Sven Ante Lundberg reported a grant of 10,826 stock options on June 12, 2026 at an exercise price of $12.64 per share, expiring June 11, 2036. The options vest in full upon the earlier of June 12, 2027 or the next annual stockholders’ meeting, and this Form 4/A corrects the number of options originally reported.
Q32 Bio Inc. director Kathleen LaPorte received a grant of 10,826 stock options on June 12, 2026 at an exercise price of $12.64 per share, expiring June 11, 2036. This amendment corrects the previously reported grant size. The options vest in full on the earlier of June 12, 2027 or the next annual meeting of stockholders, subject to her continued service.
Q32 Bio Inc. director Mark T. Iwicki reported a compensation award of stock options for 10826.0000 shares of common stock, granted on June 12, 2026 at an exercise price of $12.6400 per share and expiring June 11, 2036. The options vest in full on the earlier of June 12, 2027 or the issuer's next annual meeting of stockholders, subject to his continued service. This Form 4 amendment corrects the number of options previously reported for this grant.
An amended Form 4 for Q32 Bio Inc. reports that director and 10% owner Diyong Xu received a grant of 10,826 stock options on June 12, 2026 at a $12.64 exercise price, vesting by June 12, 2027 or the next annual meeting, with benefits required to be passed through to specified OrbiMed investment entities.
Q32 Bio Inc. director Isaac Manke received a grant of stock options for 10,826 shares of common stock on June 12, 2026 at an exercise price of $12.64 per share, expiring on 2036-06-11. This amendment corrects the option amount previously reported. The options vest in full on the earlier of June 12, 2027 or the issuer’s next annual meeting of stockholders, subject to his continued service.
Q32 Bio Inc. director David S. Grayzel received a corrected grant of stock options covering 10,826 shares of common stock at an exercise price of $12.64 per share, expiring on June 11, 2036.
The options vest in full on the earlier of June 12, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Any proceeds from sales of shares issued on exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims beneficial ownership except for any pecuniary interest.
Q32 Bio Inc. director Mary Thistle received a corrected grant of 10,826 stock options on June 12, 2026. The options have an exercise price of $12.64 per share, expire on June 11, 2036, and vest in full on the earlier of June 12, 2027 or the next annual stockholders’ meeting, subject to continued service.
Q32 Bio Inc. reported that Chief Scientific Officer Shelia M. Violette acquired 37,500 shares of common stock on July 16, 2026 from the vesting of performance-based restricted stock units tied to a financing of at least $100,000,000 in gross proceeds. These PSUs are also subject to a time-based condition and will vest in equal quarterly installments over three years from July 1, 2026, contingent on her continued service. Following this award, she holds 130,569 shares directly and 36,277 shares indirectly through Violette Holdings LLC, where she disclaims beneficial ownership beyond any pecuniary interest.
Q32 Bio Inc. CEO Jodie Pope Morrison reported an acquisition of 132,000 shares of common stock tied to performance-based restricted stock units granted on July 6, 2026. The PSUs met a financing performance condition and remain subject to quarterly vesting over three years, bringing her direct holdings to 353,104 shares.
Q32 Bio Inc. officer Lee Kalowski, its CFO and President, reported an acquisition of 53,250 shares of common stock on July 16, 2026, via a grant of performance-based restricted stock units (PSUs). Each PSU represents a contingent right to one share, and his direct holdings increased to 142,443 shares.
The PSUs were granted on July 6, 2026 and are tied to a performance-based condition linked to the closing of a financing of at least $100,000,000 in gross proceeds on or before December 31, 2026, and a time-based condition under which they vest in equal quarterly installments over three years from July 1, 2026, subject to continued service.
Q32 Bio Inc. director Isaac Manke exercised stock options to acquire 53,521 shares of Common Stock on June 30, 2026 at an effective exercise price of $2.80 per share. Following the exercise, he directly holds 53,521 common shares and the corresponding option position reported in this filing has been fully exercised.
The exercised option, described as a Stock Option (Right to Buy), had granted rights over 53,521 shares of Common Stock and was fully vested and exercisable. After this transaction, the derivative position shown in the filing has a reported balance of 0 options, indicating a complete exercise of this award with no sale reported in this filing.
Q32 Bio Inc. director Kathleen LaPorte received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options vest in full on the earlier of June 12, 2027 or the company’s next annual stockholder meeting, subject to her continued service, and represent her entire reported option position in this filing.
Q32 Bio Inc. director Mark T. Iwicki received a grant of stock options covering 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. They vest in full on the earlier of June 12, 2027 or the company’s next annual stockholder meeting, contingent on his continued service.
Q32 Bio Inc. director Isaac Manke received a grant of stock options covering 9,810 shares of common stock. These options have an exercise price of $12.64 per share and were awarded as compensation, not through an open-market purchase or sale.
The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, subject to Manke’s continued board service on that vesting date. Following this grant, he holds 9,810 derivative securities tied to Q32 Bio common stock directly.
Q32 Bio Inc. director Arthur Tzianabos received a grant of stock options representing 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. Following this grant, he holds 9,810 options directly from this award in this filing.
According to the vesting terms, these options will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided he continues to serve with the company through the applicable vesting date.
Q32 Bio Inc. director David S. Grayzel received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options vest in full on the earlier of June 12, 2027 or the issuer’s next annual stockholder meeting, subject to his continued service. Any proceeds from sales of shares issued upon exercise are to be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims ownership except for any pecuniary interest.
Q32 Bio Inc. director Mary Thistle received a grant of stock options representing 9,810 shares of common stock. These options have an exercise price of $12.64 per share and expire on June 11, 2036. Following this grant, she holds 9,810 options directly.
The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, as long as she continues serving on the board through that vesting date.
Q32 Bio Inc. director and ten percent owner Diyong Xu received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options expire on June 11, 2036.
The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, subject to Xu’s continued service. Under an agreement with OrbiMed entities, any securities or economic benefits from these options must be transferred to OrbiMed-related funds.
Q32 Bio Inc. director Sven Ante Lundberg received a grant of stock options covering 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase.
All 9,810 underlying shares will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided Lundberg continues serving as a director through that vesting date.
Q32 Bio Inc. director and 10% owner Diyong Xu reported indirect purchases totaling 1,875,000 shares of common stock at $8.00 per share. The shares were acquired by affiliated OrbiMed investment funds in a private placement directly from Q32 Bio, with one fund’s indirect holdings reaching 3,502,987 shares after the transactions.
Q32 Bio Inc. reported significant insider buying by OrbiMed-affiliated investment entities. On May 28, 2026, these entities purchased a total of 1,875,000 shares of Q32 Bio common stock at $8.00 per share in a private placement directly from the company.
Following these transactions, one OrbiMed-related account holds 3,502,987 shares of common stock and another holds 625,000 shares, both reported as indirect ownership. The OrbiMed entities, which are 10% owners and have a board representative at Q32 Bio, disclaim beneficial ownership beyond their pecuniary interests.
Violette Shelia M. reported acquisition or exercise transactions in this Form 4 filing.
Q32 Bio Inc. Chief Scientific Officer Shelia M. Violette received a grant of 37,500 restricted stock units on February 24, 2026, at no cash cost per unit. The RSUs vest in four equal installments: 25% after 6 months from the grant date and 25% after 12, 24, and 36 months, with each RSU representing one share of common stock.
After this award, she directly holds 93,069 common shares. She is also a manager of Violette Holdings LLC, which holds 36,277 common shares; she disclaims beneficial ownership of those indirect shares except to the extent of her pecuniary interest.
Q32 Bio Inc. reported that its CFO and President, Lee Kalowski, received an equity award of 53,250 shares of common stock in the form of restricted stock units. This is a compensation-related grant at a price of $0.00 per share, not an open‑market purchase.
The RSUs vest in four equal 25% installments starting six months after the February 24, 2026 grant date, then at 12, 24, and 36 months from that date. Each RSU converts into one share of common stock upon vesting. After this grant, Kalowski holds 89,193 shares directly.
Morrison Jodie Pope reported acquisition or exercise transactions in this Form 4 filing.
Q32 Bio Inc. reported that CEO and director Jodie Pope Morrison received a grant of 132,000 shares of Common Stock on February 24, 2026 at a price of $0.0000 per share. Following this award, her directly held Common Stock position is 221,104 shares.
The award is structured as restricted stock units (RSUs). The RSUs vest in four equal 25% installments: 6, 12, 24, and 36 months from the February 24, 2026 grant date. Each RSU represents a contingent right to receive one share of Q32 Bio common stock as it vests.
Q32 Bio Inc. executive Lee Kalowski, the CFO and President, reported an automatic sale of 3,995 shares of common stock on February 25, 2026 to cover tax withholding tied to vesting of restricted stock units. The weighted average sale price was $4.5144 per share, with individual trades ranging from $4.35 to $4.69. After these transactions, Kalowski directly owned 35,943 shares of Q32 Bio common stock.
Q32 Bio Inc. CEO and director Jodie Pope Morrison reported an open-market sale of 9,896 shares of common stock on February 25, 2026 at a weighted average price of $4.5144 per share. According to the disclosure, these shares were required to be sold to cover tax withholding obligations related to the vesting of restricted stock units, and the sales were automatic and not at her discretion. The trades occurred in multiple transactions at prices ranging from $4.35 to $4.69 per share. After these sales, she directly owned 89,104 Q32 Bio shares.
Q32 Bio Inc. Chief Scientific Officer Shelia M. Violette reported an automatic sale of 2,815 shares of common stock on February 25, 2026 to cover tax withholding from vesting restricted stock units. The weighted average sale price was $4.5144 per share, across trades between $4.35 and $4.69.
After this sale, she held 55,569 shares directly. An additional 36,277 shares were reported as held indirectly through Violette Holdings LLC, for which she disclaims beneficial ownership except for any pecuniary interest.
Q32 Bio director Kathleen LaPorte reported a new stock option grant. On 01/15/2026, she received a stock option to buy 23,272 shares of Q32 Bio Inc. common stock with a $3.60 exercise price, under the 2024 Stock Option and Incentive Plan and the non-employee director compensation policy.
The option vests in four equal quarterly installments on the last day of each calendar quarter, as long as she continues serving as a director. LaPorte elected to receive stock options instead of cash retainer fees, and the company notes this award was initially omitted from prior reports due to administrative oversight.
Q32 Bio Inc. director David S. Grayzel reported a grant of stock options on January 15, 2026 under the company’s 2024 Stock Option and Incentive Plan and non-employee director compensation policy. The award covers 16,363 options with an exercise price of $2.75 per share.
The options vest in four equal quarterly installments on the last day of each calendar quarter, conditioned on his continued service, and were elected in lieu of cash retainer fees. The filing notes the grant was initially omitted due to administrative oversight. Any proceeds from sales of shares issued on exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims beneficial ownership except for any pecuniary interest.
Q32 Bio Inc. reported that director Sven Ante Lundberg received a grant of stock options on January 15, 2026. The award covers 20,363 stock options to buy Q32 Bio common stock at an exercise price of $2.75 per share.
The options were granted under the company’s 2024 Stock Option and Incentive Plan and its non-employee director compensation policy, reflecting Lundberg’s election to receive options instead of cash retainer fees. The grant vests in four equal quarterly installments, each at the end of a calendar quarter, conditioned on continued board service. The filing notes the award was initially not reported due to administrative oversight.
Q32 Bio (QTTB) reported a director stock option grant on a Form 4. The director was awarded 53,521 stock options at an exercise price of $2.80 per share on 10/23/2025, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual meeting of stockholders, subject to continued service. Following the transaction, the director beneficially owns 53,521 derivative securities, held directly.
Q32 Bio (QTTB) reported a director’s stock option grant on a Form 4. On 10/23/2025, the director acquired 53,521 stock options (Code A) with an exercise price of $2.80 per share, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual stockholder meeting, contingent on continued service. Following this transaction, the director beneficially owns 53,521 derivative securities, held directly. The price of the derivative security was listed as $0.00.
Q32 Bio (QTTB) reported a director stock option grant. On 10/23/2025, the reporting person received a stock option for 53,521 shares at an exercise price of $2.80 per share. Following the transaction, 53,521 derivative securities were beneficially owned directly.
The option vests in full upon the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service, and expires on 10/22/2035. The filing lists the grant as an acquisition.
Q32 Bio Inc. (QTTB) reported a director stock option grant on a Form 4. The filing lists a stock option (right to buy) for 53,521 shares at an exercise price of $2.80, dated 10/23/2025, with an expiration on 10/22/2035. The option acquisition is recorded at $0.00 for the derivative security.
Vesting occurs in full on the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service. The ownership form is listed as Direct. A footnote states the reporting person is obligated, pursuant to an agreement, to transfer any securities or economic benefits from such awards to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will ensure they are provided to OrbiMed Private Investments VII, LP.
Q32 Bio (QTTB) reported a director stock option grant on a Form 4. On 10/23/2025, the director was awarded 53,521 stock options at an exercise price of $2.80 per share. The options expire on 10/22/2035 and will vest in full on the earlier of 10/23/2026 or the company’s next annual stockholder meeting, subject to continued service. Following the grant, the director beneficially owns 53,521 derivative securities directly.
Q32 Bio (QTTB) reported a director equity grant on a Form 4. On 10/23/2025, the director was granted a stock option for 53,521 shares at an exercise price of $2.8 per share, expiring on 10/22/2035. The option vests in full upon the earlier of October 23, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continued service. Following the grant, 53,521 derivative securities were beneficially owned in direct form.
The filing notes that proceeds of any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and the Reporting Person disclaims ownership except to the extent of any pecuniary interest.
Q32 Bio (QTTB) reported a Form 4 for a director reflecting a grant of stock options. The filing lists a Stock Option (Right to Buy) for 53,521 shares at an exercise price of $2.8 per share on 10/23/2025.
These options vest in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service on the vesting date. The option carries an expiration date of 10/22/2035 and is held directly. The grant price for the derivative security is shown as $0.00, consistent with option awards.
Q32 Bio Inc. (QTTB) reported an insider equity award on a Form 4. A director received a stock option grant covering 53,521 shares on 10/23/2025, with an exercise price of $2.80 per share and an expiration date of 10/22/2035. Ownership of the derivative security is listed as Direct.
The option vests in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the director’s continued service through that date. Following the reported transaction, the director beneficially owned 53,521 derivative securities.